CRL Global Services Builds European Lab in UK
CRL Global Services (Kansas), an independent clinical testing laboratory operation, has concluded a deal with Quotient Bioresearch (Cambridgeshire, UK) that will see CRL Global Services establish its new European laboratory hub in the UK.
CRL Global Services has chosen to construct its own laboratory in Cambridgeshire, UK, embedded within the existing facilities of Quotient Bioresearch. It will provide a further full service laboratory arm to CRL Global Services’ existing global structure. The contract also provides for an immediate close collaboration between the companies on the development and delivery of new services, particularly in the areas of bioanalysis, biomarkers, and microbiology.
David Griffiths, PhD MBA, business development director, Quotient Bioresearch, added: “We are very pleased to be working together with CRL Global Services as they construct their new laboratory in the UK. The established capabilities of the two companies are entirely complementary. I anticipate synergies that will enable us to deliver a joint offering significantly broader than available from each party working alone.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
